2 terminated, 1 completed, 1 withdrawn. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 2, Completed 1, Withdrawn 1 |
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
Follow Blasts 5 Percent or More of Bone Marrow Nucleated Cells: new trials by email Literature Review of Blasts 5 Percent or More of Bone Marrow Nucleated Cells trials Research Report on Blasts 5 Percent or More of Bone Marrow Nucleated Cells
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome - Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-01-21 | 2022-01-28 | |
| ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia ADCT-602 - Blasts 5 Percent or More of Bone Marrow Nucleated Cells, CD22 Positive | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 37 | 2018-08-24 | 2025-12-12 |
| EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells | Phase 1 | Terminated | University of Southern California | 3 | 2018-05-09 | 2021-11-30 |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2015-12-16 | 2022-06-30 |
Burkitt Lymphoma (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1) · Myelodysplastic-Myeloproliferative Diseases (1) · Neoplasm, Residual (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Lymphoma (3) · Chronic Disease (2) · DNA Virus Infections (2) · Disease Attributes (2) · Epstein-Barr Virus Infections (2) · Hematologic Diseases (2) · Herpesviridae Infections (2) · Infections (2)
Vincristine (2) · CTL019 chimeric antigen receptor (1) · Cyclophosphamide (1) · Cytarabine (1) · Inotuzumab Ozogamicin (1) · fludarabine phosphate (1) · tisagenlecleucel (1)
M.D. Anderson Cancer Center (2) · Roswell Park Cancer Institute (1) · University of Southern California (1)
United States (4)
Akil Merchant, MD (1) · Eunice S Wang (1) · Nitin Jain (1) · Partow Kebriaei (1)
P30CA014089 (1)